Product Information
NEBIVOLOL 2.5 MG TABLET is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.1169 per EA under NDC 62559027583. Its NADAC has been published 208 times since Oct 12, 2022.
FDA first approved this application on Apr 16, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Nebivolol market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2.5 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559027583
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NEBIVOLOL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203659FDA Approved
4/16/2015
TE Code
AB
On Market Since
9/17/2021
Pharmacological Classes
Price Statistics
The NADAC for NEBIVOLOL 2.5 MG TABLET has been published 208 times since Oct 12, 2022, and over the history we have for it it has declined 57.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1169 per EA |
|---|---|
| All-time high | $0.2720 (Oct 12, 2022) |
| All-time low | $0.0694 (Jul 17, 2024) |
| 52-week high | $0.1288 |
| 52-week low | $0.1044 |
| Median price | $0.1189 |
| Average price | $0.1353 |
| Largest weekly change | -34.4% (Jul 17, 2024) |
| Weeks tracked | 208 |
| Tracking since | Oct 12, 2022 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 13% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Nebivolol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEBIVOLOL 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NEBIVOLOL 2.5 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $0.1169 per EA (NDC 62559027583), effective Sep 30, 2026.
How has the price of NEBIVOLOL 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for NEBIVOLOL 2.5 MG TABLET has declined 57.0%. It has been tracked across 208 weekly CMS publications since Oct 12, 2022.
What are the highest and lowest recorded NADAC prices for NEBIVOLOL 2.5 MG TABLET?
Since Oct 12, 2022, the NADAC for NEBIVOLOL 2.5 MG TABLET has ranged from a low of $0.0694 (Jul 17, 2024) to a high of $0.2720 (Oct 12, 2022), with a median of $0.1189 per EA.
Are there cheaper alternatives to NEBIVOLOL 2.5 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NEBIVOLOL 2.5 MG TABLET, is $0.1012 per EA — about 13% below NEBIVOLOL 2.5 MG TABLET.
Who manufactures NEBIVOLOL 2.5 MG TABLET?
NEBIVOLOL 2.5 MG TABLET (NDC 62559027583) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.